M. Bastide, T. Ouk, F. Plaisier, O. Pétrault, S. Stolc, and R. Bordet, “Neurogliovascular unit after cerebral ischemia: is the vascular wall a pharmacological target,” Psychoneuro-endocrinology, Vol. 32 Suppl 1, No. 1, 2007, pp. S36-39.
 C. Richter-Landsberg and U. Vollgraf, “Mode of cell injury and death after hydrogen peroxide exposure in cultured oligodendroglia cells,” Experimental Cell Re- search, Vol. 244, No. 1, 1998, pp. 218-229.
 C.A. Tegla, C. Cudrici, V. Rus, T. Ito, S. Vlaicu, A. Singh, and H. Rus, “Neuroprotective effects of the com-plement terminal pathway during demyelination: implica-tions for oligodendrocyte survival,” Journal of Neuro-immunology, Vol. 213, No. 1-2, 2009, pp. 3-11.
 A. Jana and K. Pahan, “Oxidative Stress Kills Human Primary Oligodendrocytes Via Neutral Sphingomyelinase: Implications for Multiple Sclerosis,” Journal of Neuro- immune Pharmacology, Vol. 2, No. 1, 2007, pp. 184-193.
 M. Vanmeeteren, J. Hendriks, C. Dijkstra, and E. Vantol, “Dietary compounds prevent oxidative damage and nitric oxide production by cells involved in demyelinating dis- ease,” Biochemical Pharmacology, Vol. 67, No. 5, 2004, pp. 967-975.
 C. Matute, E. Alberdi, M. Domercq, M.-V. Sán-chez- Gómez, A. Pérez-Samartín, A. Rodríguez-Antigüedad, and F. Pérez-Cerdá, “Excitotoxic damage to white matter,” Journal of Anatomy, Vol. 210, No. 6, 2007, pp. 693-702.
 Y. Zhang, C. Taveggia, C. Melendez-Vasquez, S. Ein- heber, C.S. Raine, J.L. Salzer, C.F. Brosnan, and G.R. John, “Interleukin-11 potentiates oligodendrocyte sur- vival and maturation, and myelin formation,” The Jour- nal of Neuroscience, Vol. 26, No. 47, 2006, pp. 12174- 12185.
 S. A Back, N.L. Luo, N.S. Borenstein, J.M. Levine, J.J. Volpe, and H.C. Kinney, “Late oligodendrocyte progeni-tors coincide with the developmental window of vulner-ability for human perinatal white matter injury,” The Journal of Neuroscience, Vol. 21, No. 4, 2001, pp. 1302-12.
 Y. Pang, L. Campbell, B. Zheng, L. Fan, Z. Cai, and P. Rhodes, “Lipopolysaccharide-activated microglia induce death of oligodendrocyte progenitor cells and impede their development,” Neuroscience, Vol. 166, No. 2, 2010, pp. 464-475.
 J.J. Volpe, H.C. Kinney, E.J. Frances, and P.A. Rosen- berg (In press), “The developing oligodendrocyte: key cellular target in brain injury in the premature infant,” International Journal of Developmental Neuroscience.
 R. Talac, J.A. Friedman, M.J. Moore, L. Lu, E. Jabbari, A.J. Windebank, B.L. Currier, and M.J. Yaszemski, “Animal models of spinal cord injury for evaluation of tissue engineering treatment strategies,” Biomaterials, Vol. 25, No. 9, 2004, pp. 1505-1510.
 Y.H. Ahn, G. Lee, and S.K. Kang, “Molecular insights of the injured lesions of rat spinal cords: Inflammation, apoptosis, and cell survival,” Biochemical and Biophysi-cal Research Communications, Vol. 348, No. 1, 2006, pp. 560-570.
 B.D. Butts, C. Houde, and H. Mehmet, “Matura-tion- dependent sensitivity of oligodendrocyte lineage cells to apoptosis: implications for normal development and disease,” Cell Death and Differentiation, Vol. 15, No. 1, 2008, pp. 1178-1186.
 A.D. Roth, G. Ramírez, and R. Alarcón, R.V. Bernhardi, “Oligodendrocytes damage in Alzheimer’ s disease : Beta amyloid toxicity and inflammation,” Biological Re-search, Vol. 38, No. 1, 2005, pp. 381-387.
 N.A. Uranova, V.M. Vostrikov, O.V. Vikhreva, I.S. Zi-mina, N.S. Kolomeets, and D.D. Orlovskaya, “The role of oligodendrocyte pathology in schizophrenia.,” The In-ternational Journal of Neuropsychopharmacology, Vol. 10, No. 4, 2007, pp. 537-545.
 P.R. Hof, V. Haroutunian, C. Copland, K.L. Davis, and J.D. Buxbaum, “Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia,” Neuro- chemical Research, Vol. 27, No. 10, 2002, pp. 1193- 1200.
 D. Segal, J.R. Koschnick, L.H.A. Slegers, and P.R. Hof, “Oligodendrocyte pathophysiology: a new view of schi- zophrenia.,” The International Journal of Neuropsycho- pharmacology, Vol. 10, No. 4, 2007, pp. 503-511.
 K. Sano, K. Morii, M. Sato, H. Mori, and R. Tanaka, “Radiation-induced diffuse brain injury in the neonatal rat model--radiation-induced apoptosis of oligodendro- cytes,” Neurologia Medico-Chirurgica, Vol. 40, No. 10, 2000, pp. 495-499.
 A. Ernst, A. Stolzing, G. Sandig, and T. Grune, “Anti-oxidants effectively prevent oxidation-induced protein damage in OLN 93 cells,” Archives of Biochemistry and Biophysics, Vol. 421, No. 1, 2004, pp. 54-60.
  H. Mann, M.T. McCoy, J. Subramaniam, H.V. Remmen, and J.L. Cadet, “Overexpression of superoxide dismutase and catalase in immortalized neural cells: toxic effects of hydrogen peroxide,” Brain Research, Vol. 770, No. 1, 1997, pp. 163-168.
 E.A. Leuchtmann, A.E. Ratner, R. Vijitruth, Y. Qu, and J.W. Mcdonald, “AMPA receptors are the major media-tors of excitotoxic death in mature oligodendrocytes,” Neurobiology of Disease, Vol. 14, No. 1, 2003, pp. 336- 348.
 W. Cammer and H. Zhang, “Maturation of oligodendro- cytes is more sensitive to TNF-a than is survival of pre- cursors and immature oligodendrocytes,” Journal of Neuroimmunology, Vol. 97, No. 1, 1999, pp. 37-42.
 W. Cammer, “Protection of cultured oligodendrocytes against tumor necrosis factor-alpha by the antioxidants coenzyme Q(10) and N-acetyl cysteine,” Brain Research Bulletin, Vol. 58, No. 6, 2002, pp. 587-592.
 J.L. Takahashi, F. Giuliani, C. Power, Y. Imai, and V.W. Yong, “Interleukin-1beta promotes oligodendrocyte death through glutamate excitotoxicity,” Annals of Neurology, Vol. 53, No. 5, 2003, pp. 588-595.
 T.Y. Yune, J.Y. Lee, G.Y. Jung, S.J. Kim, M.H. Jiang, Y.C. Kim, Y.J. Oh, G.J. Markelonis, and T.H. Oh, “Mi-nocycline alleviates death of oligodendrocytes by inhib-iting pro-nerve growth factor production in microglia af-ter spinal cord injury,” The Journal of Neuroscience, Vol. 27, No. 29, 2007, pp. 7751-7761.
 Y. Nakamura, Q. Feng, T. Kumagai, K. Torikai, H. Ohi-gashi, T. Osawa, N. Noguchi, E. Niki, and K. Uchida, “Ebselen , a Glutathione Peroxidase Mimetic Se-leno- organic Compound , as a Multifunctional Antioxi-dant,” The Journal of Biological Chemistry, Vol. 277, No. 4, 2002, pp. 2687-2694
 Y. Ueno, N. Zhang, N. Miyamoto, R. Tanaka, N. Hattori, and T. Urabe, “Edaravone attenuates white matter lesions through endothelial protection in a rat chronic hypoperfu-sion model,” Neuroscience, Vol. 162, No. 2, 2009, pp. 317-327.
 J.-M. Lee, P. Yan, Q. Xiao, S. Chen, K.-Y. Lee, C.Y. Hsu, and J. Xu, “Methylprednisolone protects oligodendro- cytes but not neurons after spinal cord injury,” The Jour- nal of Neuroscience, Vol. 28, No. 12, 2008, pp. 3141- 3149.
 D.D. Rowe, C.C. Leonardo, A.A. Hall, M.D. Shahaduz-zaman, L.A. Collier, A.E. Willing, and K.R. Pennypacker, “Cord blood administration induces oligodendrocyte sur-vival through alterations in gene expression,” Brain Re-search, Vol. 1366, No. 1, 2010, pp. 172-188.
 S. Genc, K. Genc, A. Kumral, and H. Ozkan, “White matter protection by erythropoietin: an emerging matter in the treatment of neonatal hypoxic-ischemic brain in-jury,” Stroke, Vol. 41, No. 11, 2010, p. e595.
 B.G. Xiao, X.F. Bail, G.X. Zhang, G. Hedlund, and H. Link, “Linomide-mediated protection of oligodendro- cytes is associated with inhibition of nitric oxide produc- tion and IL-1beta expression in Lewis rat glial cells,” Neuroscience Letters, Vol. 249, No. 1, 1998, pp. 17-20.
 E.-J. Lee, M.-Y. Lee, H.-Y. Chen, Y.-S. Hsu, T.-S. Wu, S.-T. Chen, and G.-L. Chang, “Melatonin attenuates gray and white matter damage in a mouse model of transient focal cerebral ischemia,” Journal of Pineal Research, Vol. 38, No. 1, 2005, pp. 42-52.
 R. Takano, S. Hisahara, K. Namikawa, H. Kiyama, H. Okano, and M. Miura, “Nerve growth factor protects oli-godendrocytes from tumor necrosis factor-alpha-induced injury through Akt-mediated signaling mechanisms,” The Journal of Biological Chemistry, Vol. 275, No. 21, 2000, pp. 16360-16365.
 J.-S. Kim, I. Yun, Y.B. Choi, K.-S. Lee, and Y.-I. Kim, “Ramipril protects from free radical induced white matter damage in chronic hypoperfusion in the rat,” Journal of Clinical Neuroscience, Vol. 15, No. 2, 2008, pp. 174-178.
 R. Fern, B.R. Ransom, P.K. Stys, and S.G. Waxman, “Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine and diaze-pam,” The Journal of Pharmacology and Experimental Therapeutics, Vol. 266, No. 3, 1993, pp. 1549-1555.
 W.H. Lagarde, R. Benjamin, A.T. Heerens, P. Ye, R.I. Cohen, B.M. Moats-staats, and A.J. D’ercole, “A non- transformed oligodendrocyte precursor cell line, OL-1, facilitates studies of insulin-like growth factor-I signaling during oligodendrocyte development,” Interna-tional Journal of Developmental Neuroscience, Vol. 25, No. 2, 2007, pp. 95-105.
 F.A. McMorris, T.M. Smith, S. DeSalvo, and R.W. Fur- lanetto, “Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development,” Pro- ceedings of the National Academy of Sciences of the United States of America, Vol. 83, No. 3, 1986, pp. 822-826.
 J.L. Mason, S. Xuan, I. Dragatsis, A. Efstratiadis, and J.E. Goldman, “Insulin-like growth factor (IGF) signaling through type 1 IGF receptor plays an important role in remyelination,” The Journal of Neuroscience, Vol. 23, No. 20, 2003, pp. 7710-7718.
 S.A. Jones, D.M. Jolson, K.K. Cuta, C.N. Mariash, and G.W. Anderson, “Triiodothyronine is a survival factor for developing oligodendrocytes,” Molecular and Cellular Endocrinology, Vol. 199, No. 1-2, 2003, pp. 49-60.
 M. Sugawa, Y. Sakurai, Y. Ishikawa-ieda, H. Suzuki, and H. Asou, “Effects of erythropoietin on glial cell devel-opment; oligodendrocyte maturation and astrocyte prolif-eration,” Neuroscience Research, Vol. 44, No. 4, 2002, pp. 391-403.